Immuntherapie und Tyrosinkinaseinhibitoren beim metastasierten Nierenzellkarzinom in der First-line-Therapie – Wann welche Strategie?

Immunotherapies with checkpoint inhibitors have led to a paradigm shift in metastatic renal cell carcinoma (mRCC) as they established a new standard in first-line treatment. In addition to the established monotherapy with tyrosine kinase inhibitors, the spectrum of first-line options has now become...

Descripción completa

Detalles Bibliográficos
Autores principales: Mickisch, G., Peters, I., Grüllich, C., Mudra, T., Doehn, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2020
Materias:
Übersichten
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873000/
https://www.ncbi.nlm.nih.gov/pubmed/33026489
http://dx.doi.org/10.1007/s00120-020-01320-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873000/
https://www.ncbi.nlm.nih.gov/pubmed/33026489
http://dx.doi.org/10.1007/s00120-020-01320-8

Ejemplares similares